Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Surg Clin North Am. 2019 Nov 1;100(1):141–159. doi: 10.1016/j.suc.2019.09.012

Table 3.

Active Neoadjuvant Melanoma Clinical Trials

Trial Neoadjuvant Treatment Treatment Duration Primary Endpoint Estimated Completion
Immunotherapy
Group A:_Nivolumab
Group B: Nivolumab + Ipilimumab
Neoadjuvant: 7 weeks
Adjuvant: 6 months
Pathologic complete response 2020
Nivolumab + HF 10 12 weeks Pathologic complete response 2022
Pembrolizumab
Procedure: Surgery
Radiation: IMRT
12 weeks Disease free survival 2025
Pembrolizumab and high dose interferon alfa-2b (HDI) 6–8 weeks Adverse events 2019
Group A: Dabrafenib + Trametinib THEN Pembrolizumab
Group B: Dabrafenib + Trametinib + Pembrolizumab
Group C: Pembrolizumab ONLY
Neoadjuvant: 6 weeks
Adjuvant: 46 weeks
Pathologic complete response 2019
Ipilimumab + Nivolumab 6 weeks Response rate Recurrence free survival 2020
Pembrolizumab One dose Number of adverse events 2022
Pembrolizumab 9 weeks Event-free survival 2022
Group A: VX15/2503 + Nivolumab + surgery
Group B: VX15/2503 + Ipilimumab + surgery
Group C: VX15/2503 + Nivolumab + Ipilimumab Group D: VX15/2503 + surgery
Two doses Extent of CD8 T-cell infiltration following treatment 2031
Targeted Therapy
Drug: Vemurafenib + Cobimentinib 8 weeks Resectability rate 2022
Drug: Dabrafenib + Trametinib 8 weeks Relapse-free survival 2019
Drug: Vemurafenib + Cobimentinib 4 weeks Resectability rate 2019
Group A: Atezolizumab + Vemurafenib + Cobimentinib
Group B: Atezolizumab + Cobimentinib
12 weeks Pathologic complete response 2023
Group A: Dabrafenib + Trametinib THEN Pembrolizumab
Group B: Dabrafenib + Trametinib + Pembrolizumab
Group C: Pembrolizumab ONLY
Neoadjuvant: 6 weeks
Adjuvant: 46 weeks
Pathological response rate
Resectability rate
2019
Other Therapies
GM-CSF 14 days Th1/Th2 ratio 2019
Daromun 4 weeks Recurrence free survival 2020